Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: A population-based study
Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: A population-based study
复制标题
DOI：
10.1016/s0169-5002(98)00039-7
复制
发表时间：
1998-08-01
期刊：
影响因子：
5.3
通讯作者：
Coebergh, JWW
中科院分区：
文献类型：
--
作者：
Janssen-Heijnen, MLG;Schipper, RM;Coebergh, JWW
背景：随着肺癌患者平均年龄的上升，诊断时患有严重合并症的患者数量也在增加。因此，合并症可能成为治疗选择和生存的重要因素。我们研究了新诊断肺癌患者中严重合并症的患病率及其与形态、分期和治疗的关系。患者：1993年至1995年间，共有3864名肺癌患者在南方综合癌症中心的人口登记处登记。结果：在研究期间，患者的平均年龄为67岁（范围：29-93岁）。最常见的伴随疾病是心血管疾病（23%）、慢性阻塞性肺疾病（COPD）（22%）和其他恶性肿瘤（15%）。男性（60%）、鳞状细胞癌患者（64%）和局限性肿瘤患者（66%）的伴随疾病患病率最高。与无伴随疾病的患者 (94%) 相比，年龄 < 70 岁、患有局限性非小细胞肺肿瘤的患有慢性阻塞性肺病 (67%) 或糖尿病 (64%) 的患者的切除率尤其低。小细胞肺癌患者的合并症与化疗之间的关联有限。结论：肺癌患者的合并症，尤其是心血管疾病和慢性阻塞性肺病的患病率约为普通人群的两倍。合并症似乎与肺癌的早期诊断有关，但也可能导致分期不准确和治疗不积极。因此，预后可能会受到共病的负面影响。 (C) 1998 Elsevier Science, Ireland, Ltd. 版权所有。预订的。
Background: With the rising mean age of lung cancer patients, the number of patients with serious co-morbidity at diagnosis is increasing. As a result, co-morbidity may become an important factor in both the choice of treatment and survival. We studied the prevalence of serious co-morbidity among newly diagnosed lung cancer patients and its association with morphology, stage and treatment. Patients: A total of 3864 lung cancer patients registered in the population-based registry of the Comprehensive Cancer Centre South between 1993 and 1995. Results: During the study period, the mean age of patients was 67 years (range: 29-93). The most frequent concomitant diseases were cardiovascular diseases (23%), chronic obstructive pulmonary diseases (COPD) (22%) and other malignancies (15%). The prevalence of concomitant diseases was highest for men (60%), patients with squamous-cell carcinoma (64%) and those with a localised tumour (66%). The resection rate for patients < 70 years, with a localised non-small-cell lung tumour, was especially low for those with COPD (67%) or diabetes (64%) compared with patients without concomitant diseases (94%). The association between co-morbidity and chemotherapy for patients with small-cell lung cancer was limited. Conclusions: The prevalence of co-morbidity, especially cardiovascular diseases and COPD, among lung cancer patients is about twice as high as in the general population. Co-morbidity seems to be associated with earlier diagnosis of lung cancer, but it may also lead to less accurate staging and less aggressive treatment. Thus, prognosis is likely to be negatively influenced by co-morbidity. (C) 1998 Elsevier Science, Ireland, Ltd. All rights. reserved.